Gene Editing

© GettyImages/ipopba

Urgent action needed to reduce high costs of gene therapies

By Jane Byrne

The extremely high costs of gene therapies are unsustainable, and a global commitment to affordable, equitable access to these treatments is urgently needed, concluded the organising committee of a conference on human genome editing.

CRISPR-Cas9 is a tool for gene editing that is faster and more precise than traditional options. (Image: iStock)

Evotec licenses CRISPR gene editing tech

By Melissa Fassbender

Evotec AG has entered into a non-exclusive license agreement with the MIT’s Broad Institute and Harvard for the use of CRISPR-Cas9 gene editing technology.